JP2010143941A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010143941A5 JP2010143941A5 JP2010019796A JP2010019796A JP2010143941A5 JP 2010143941 A5 JP2010143941 A5 JP 2010143941A5 JP 2010019796 A JP2010019796 A JP 2010019796A JP 2010019796 A JP2010019796 A JP 2010019796A JP 2010143941 A5 JP2010143941 A5 JP 2010143941A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- aminophospholipid
- binding
- antibody
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 74
- 239000003446 ligand Substances 0.000 claims description 38
- 210000004204 blood vessel Anatomy 0.000 claims description 25
- 230000008685 targeting Effects 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 108010000499 Thromboplastin Proteins 0.000 claims description 14
- 102000002262 Thromboplastin Human genes 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 11
- 210000005166 vasculature Anatomy 0.000 claims description 11
- 230000001939 inductive effect Effects 0.000 claims description 7
- 230000002792 vascular Effects 0.000 claims description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
- 239000003053 toxin Substances 0.000 claims description 6
- 206010054094 Tumour necrosis Diseases 0.000 claims description 5
- 231100000765 toxin Toxicity 0.000 claims description 5
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 239000003114 blood coagulation factor Substances 0.000 claims description 4
- 230000015271 coagulation Effects 0.000 claims description 4
- 238000005345 coagulation Methods 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 230000002022 anti-cellular effect Effects 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 18
- 229940124597 therapeutic agent Drugs 0.000 claims 9
- 210000003556 vascular endothelial cell Anatomy 0.000 claims 5
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 4
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 4
- 102000023732 binding proteins Human genes 0.000 claims 4
- 108091008324 binding proteins Proteins 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- 102000000412 Annexin Human genes 0.000 claims 2
- 108050008874 Annexin Proteins 0.000 claims 2
- 206010053567 Coagulopathies Diseases 0.000 claims 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 2
- 102000003886 Glycoproteins Human genes 0.000 claims 2
- 108090000288 Glycoproteins Proteins 0.000 claims 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 102000010631 Kininogens Human genes 0.000 claims 2
- 108010077861 Kininogens Proteins 0.000 claims 2
- 230000035602 clotting Effects 0.000 claims 2
- 238000003384 imaging method Methods 0.000 claims 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 2
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 claims 2
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 claims 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 claims 1
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims 1
- 229940122029 DNA synthesis inhibitor Drugs 0.000 claims 1
- 229910052692 Dysprosium Inorganic materials 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 claims 1
- 229910052691 Erbium Inorganic materials 0.000 claims 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims 1
- 229910052688 Gadolinium Inorganic materials 0.000 claims 1
- GYHNNYVSQQEPJS-OIOBTWANSA-N Gallium-67 Chemical compound [67Ga] GYHNNYVSQQEPJS-OIOBTWANSA-N 0.000 claims 1
- GYHNNYVSQQEPJS-YPZZEJLDSA-N Gallium-68 Chemical compound [68Ga] GYHNNYVSQQEPJS-YPZZEJLDSA-N 0.000 claims 1
- 229910052689 Holmium Inorganic materials 0.000 claims 1
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 claims 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 claims 1
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 claims 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims 1
- 229910052771 Terbium Inorganic materials 0.000 claims 1
- 229940122803 Vinca alkaloid Drugs 0.000 claims 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims 1
- 229940009456 adriamycin Drugs 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229910052797 bismuth Inorganic materials 0.000 claims 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 claims 1
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 claims 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims 1
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims 1
- CBMIPXHVOVTTTL-UHFFFAOYSA-N gold(3+) Chemical compound [Au+3] CBMIPXHVOVTTTL-UHFFFAOYSA-N 0.000 claims 1
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 claims 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 claims 1
- APFVFJFRJDLVQX-YPZZEJLDSA-N indium-113 Chemical compound [113In] APFVFJFRJDLVQX-YPZZEJLDSA-N 0.000 claims 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- CZMAIROVPAYCMU-UHFFFAOYSA-N lanthanum(3+) Chemical compound [La+3] CZMAIROVPAYCMU-UHFFFAOYSA-N 0.000 claims 1
- QSHDDOUJBYECFT-AHCXROLUSA-N mercury-197 Chemical compound [197Hg] QSHDDOUJBYECFT-AHCXROLUSA-N 0.000 claims 1
- QSHDDOUJBYECFT-NJFSPNSNSA-N mercury-203 Chemical compound [203Hg] QSHDDOUJBYECFT-NJFSPNSNSA-N 0.000 claims 1
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 claims 1
- 229910052701 rubidium Inorganic materials 0.000 claims 1
- DOSGOCSVHPUUIA-UHFFFAOYSA-N samarium(3+) Chemical compound [Sm+3] DOSGOCSVHPUUIA-UHFFFAOYSA-N 0.000 claims 1
- 125000002345 steroid group Chemical group 0.000 claims 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 claims 1
- BLSRSXLJVJVBIK-UHFFFAOYSA-N vanadium(2+) Chemical compound [V+2] BLSRSXLJVJVBIK-UHFFFAOYSA-N 0.000 claims 1
- AWSFICBXMUKWSK-UHFFFAOYSA-N ytterbium(3+) Chemical compound [Yb+3] AWSFICBXMUKWSK-UHFFFAOYSA-N 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102100037362 Fibronectin Human genes 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000002596 immunotoxin Substances 0.000 description 4
- 231100000608 immunotoxin Toxicity 0.000 description 4
- 229940051026 immunotoxin Drugs 0.000 description 4
- 230000002637 immunotoxin Effects 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- -1 macromycin Chemical compound 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 102100023471 E-selectin Human genes 0.000 description 2
- 101000753253 Homo sapiens Tyrosine-protein kinase receptor Tie-1 Proteins 0.000 description 2
- 102100022007 Tyrosine-protein kinase receptor Tie-1 Human genes 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 239000000910 agglutinin Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 101800002638 Alpha-amanitin Proteins 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 102100038083 Endosialin Human genes 0.000 description 1
- 101710144543 Endosialin Proteins 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000622123 Homo sapiens E-selectin Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000016551 L-selectin Human genes 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 101710204212 Neocarzinostatin Proteins 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- RXGJTYFDKOHJHK-UHFFFAOYSA-N S-deoxo-amaninamide Natural products CCC(C)C1NC(=O)CNC(=O)C2Cc3c(SCC(NC(=O)CNC1=O)C(=O)NC(CC(=O)N)C(=O)N4CC(O)CC4C(=O)NC(C(C)C(O)CO)C(=O)N2)[nH]c5ccccc35 RXGJTYFDKOHJHK-UHFFFAOYSA-N 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000004007 alpha amanitin Substances 0.000 description 1
- CIORWBWIBBPXCG-SXZCQOKQSA-N alpha-amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1C[S@@](=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-SXZCQOKQSA-N 0.000 description 1
- CIORWBWIBBPXCG-UHFFFAOYSA-N alpha-amanitin Natural products O=C1NC(CC(N)=O)C(=O)N2CC(O)CC2C(=O)NC(C(C)C(O)CO)C(=O)NC(C2)C(=O)NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC1CS(=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 229960005502 α-amanitin Drugs 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9258998P | 1998-07-13 | 1998-07-13 | |
| US60/092,589 | 1998-07-13 | ||
| US11060098P | 1998-12-02 | 1998-12-02 | |
| US60/110,600 | 1998-12-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000558846A Division JP2002520297A (ja) | 1998-07-13 | 1999-07-12 | アミノリン脂質に結合する治療結合体を用いる癌処置方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012262623A Division JP5721693B2 (ja) | 1998-07-13 | 2012-11-30 | アミノリン脂質に結合する治療結合体を用いる癌処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010143941A JP2010143941A (ja) | 2010-07-01 |
| JP2010143941A5 true JP2010143941A5 (enExample) | 2011-05-19 |
| JP5478285B2 JP5478285B2 (ja) | 2014-04-23 |
Family
ID=26785826
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000558846A Pending JP2002520297A (ja) | 1998-07-13 | 1999-07-12 | アミノリン脂質に結合する治療結合体を用いる癌処置方法 |
| JP2010019796A Expired - Fee Related JP5478285B2 (ja) | 1998-07-13 | 2010-01-29 | アミノリン脂質に結合する結合体を用いる腫瘍血管系の処置および画像化 |
| JP2012262623A Expired - Fee Related JP5721693B2 (ja) | 1998-07-13 | 2012-11-30 | アミノリン脂質に結合する治療結合体を用いる癌処置方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000558846A Pending JP2002520297A (ja) | 1998-07-13 | 1999-07-12 | アミノリン脂質に結合する治療結合体を用いる癌処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012262623A Expired - Fee Related JP5721693B2 (ja) | 1998-07-13 | 2012-11-30 | アミノリン脂質に結合する治療結合体を用いる癌処置方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US6312694B1 (enExample) |
| EP (1) | EP1098665B9 (enExample) |
| JP (3) | JP2002520297A (enExample) |
| AT (1) | ATE230614T1 (enExample) |
| AU (1) | AU750414B2 (enExample) |
| BR (1) | BR9912053A (enExample) |
| CA (1) | CA2331789C (enExample) |
| DE (1) | DE69904831T2 (enExample) |
| ES (1) | ES2188202T3 (enExample) |
| IL (1) | IL140700A0 (enExample) |
| NZ (1) | NZ508873A (enExample) |
| WO (1) | WO2000002587A1 (enExample) |
Families Citing this family (156)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5814464A (en) * | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| HUP0001261A3 (en) * | 1997-04-30 | 2001-11-28 | Univ Washington Seattle | Method of imaging cell death in vivo |
| US7569674B2 (en) * | 1998-05-04 | 2009-08-04 | Innexus Biotechnology International Limited | Autophilic antibodies |
| US20050033033A1 (en) * | 1998-05-04 | 2005-02-10 | Heinz Kohler | Trans-membrane-antibody induced inhibition of apoptosis |
| US20040185039A1 (en) * | 2002-08-30 | 2004-09-23 | Heinz Kohler | Therapeutic applications of noncovalent dimerizing antibodies |
| US6300308B1 (en) | 1997-12-31 | 2001-10-09 | Board Of Regents, The University Of Texas System | Methods and compositions for inducing autoimmunity in the treatment of cancers |
| US20090208418A1 (en) * | 2005-04-29 | 2009-08-20 | Innexus Biotechnology Internaltional Ltd. | Superantibody synthesis and use in detection, prevention and treatment of disease |
| BR9911882A (pt) * | 1998-07-13 | 2005-02-15 | Univ Texas | Processo de tratamento de câncer empregando anticorpos a aminofosfolipìdios |
| EP1520588B1 (en) | 1998-07-13 | 2014-12-24 | Board Of Regents, The University Of Texas System | Uses of antibodies to aminophospholipids for cancer treatment |
| US6406693B1 (en) * | 1998-07-13 | 2002-06-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
| US6818213B1 (en) | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
| CA2331789C (en) * | 1998-07-13 | 2013-09-10 | Board Of Regents, The University Of Texas System | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| US6361774B1 (en) * | 1999-09-17 | 2002-03-26 | Immunomedics, Inc. | Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug |
| US20050197283A1 (en) * | 1998-10-04 | 2005-09-08 | Vascular Biogenics Ltd. | Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease |
| IL126447A (en) * | 1998-10-04 | 2004-09-27 | Vascular Biogenics Ltd | An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis |
| US6602274B1 (en) * | 1999-01-15 | 2003-08-05 | Light Sciences Corporation | Targeted transcutaneous cancer therapy |
| US6521424B2 (en) * | 1999-06-07 | 2003-02-18 | Immunex Corporation | Recombinant expression of Tek antagonists |
| DE60031576D1 (en) * | 1999-08-30 | 2006-12-07 | Wesagen | Diagnostisches assay für typ-2-heparin induzierte thrombocytopenie |
| US6777439B2 (en) * | 2000-05-30 | 2004-08-17 | Advanced Research & Technology Institute, Inc. | Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways |
| US7445802B2 (en) * | 2000-12-26 | 2008-11-04 | Yeda Research And Development Co. Ltd | Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases |
| US20040002450A1 (en) * | 2000-12-29 | 2004-01-01 | Janette Lazarovits | Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| US7132510B2 (en) * | 2000-12-29 | 2006-11-07 | Bio-Technology General (Israel) Ltd. | Specific human antibodies for selective cancer therapy |
| US20040001822A1 (en) * | 2000-12-29 | 2004-01-01 | Avigdor Levanon | Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| US20040001839A1 (en) * | 2000-12-29 | 2004-01-01 | Avigdor Levanon | Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| EP1839670A3 (en) * | 2001-02-21 | 2009-11-11 | Alavita Pharmaceuticals, Inc. | Modified Annexin Proteins and their use against thrombosis |
| US20090291086A1 (en) * | 2001-02-21 | 2009-11-26 | Alavita Pharmaceuticals, Inc. | Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia |
| US7645739B2 (en) * | 2001-02-21 | 2010-01-12 | Alavita Pharmaceuticals, Inc. | Modified annexin compositions and methods of using same |
| US7635676B2 (en) * | 2001-02-21 | 2009-12-22 | Alavita Pharmaccuticals, Inc. | Modified annexin proteins and methods for their use in organ transplantation |
| US7635680B2 (en) * | 2001-02-21 | 2009-12-22 | Alavita Pharmaceuticals, Inc. | Attenuation of reperfusion injury |
| US20050013778A1 (en) * | 2001-04-03 | 2005-01-20 | Theseus Imaging Corporation | Methods and compositions for predicting the response to a therapeutic regimen in a subject having a disease associated with cell death |
| CA2442382A1 (en) * | 2001-04-03 | 2002-10-17 | Theseus Imaging Corporation | Methods for using annexin for detecting cell death in vivo and treating associated conditions |
| US6726895B2 (en) | 2001-04-03 | 2004-04-27 | Board Of Trustees Of The Leland Stanford Junior University | Method of imaging cell death in vivo |
| DE10127712A1 (de) * | 2001-06-07 | 2002-12-19 | Torsten Witte | Anwendung von IgM-Antikörpern gegen dsDNA beim systemischen Lupus erythematodes mit Nephritis |
| US6763760B2 (en) * | 2001-07-03 | 2004-07-20 | Hansen Conly L | Machine for injecting liquids |
| DE10145254A1 (de) * | 2001-09-13 | 2003-04-10 | November Ag Molekulare Medizin | Verwendung eines Proteins zur Herstellung eines Medikaments zur Stimulierung einer inflammatorischen zellulären Immunantwort |
| WO2003028840A2 (en) * | 2001-09-27 | 2003-04-10 | Board Of Regents, The University Of Texas System | Combined compositions and methods for tumor vasculature coagulation and treatment |
| WO2003030879A1 (en) * | 2001-10-05 | 2003-04-17 | Surmodics, Inc. | Particle immobilized coatings and uses thereof |
| US7261875B2 (en) | 2001-12-21 | 2007-08-28 | Board Of Regents, The University Of Texas System | Dendritic poly (amino acid) carriers and methods of use |
| JP4242590B2 (ja) | 2002-01-11 | 2009-03-25 | 俊一 塩澤 | 慢性関節リウマチの疾患感受性遺伝子、及びその利用 |
| US20030133938A1 (en) * | 2002-01-15 | 2003-07-17 | Penichet Manuel L. | Antibody-avidin fusion proteins as cytotoxic drugs |
| US6982154B2 (en) * | 2002-02-21 | 2006-01-03 | Surromed, Inc. | Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease |
| US9745380B2 (en) * | 2002-03-01 | 2017-08-29 | Immunomedics, Inc. | RS7 antibodies |
| US20040022731A1 (en) * | 2002-04-26 | 2004-02-05 | Alexei Bogdanov | In vivo imaging of apoptosis |
| WO2003099833A2 (en) * | 2002-05-17 | 2003-12-04 | Board Of Regents, The University Of Texas System | Beta-2-glycoprotein 1 is an inhibitor of angiogenesis |
| US7354897B2 (en) * | 2002-06-07 | 2008-04-08 | Brigham & Women's Hospital, Inc. | Method and composition for inhibiting or slowing blood coagulation |
| US20040208877A1 (en) * | 2002-07-01 | 2004-10-21 | Avigdor Levanon | Antibodies and uses thereof |
| US20040202665A1 (en) * | 2002-07-01 | 2004-10-14 | Janette Lazarovits | Compositions and methods for therapeutic treatment |
| AU2003279657A1 (en) * | 2002-07-01 | 2004-01-19 | Savient Pharmaceuticals, Inc. | Compositions and methods for therapeutic treatment |
| US7714109B2 (en) * | 2002-07-15 | 2010-05-11 | Board Of Regents, The University Of Texas System | Combinations and kits for cancer treatment using selected antibodies to aminophospholipids |
| KR20110025885A (ko) * | 2002-07-15 | 2011-03-11 | 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | 포스파티딜에탄올아민에 결합하는 펩타이드, 및 바이러스 감염을 치료하는데 있어서 이의 용도 |
| US7378386B2 (en) | 2002-07-15 | 2008-05-27 | Board Of Regents, The University Of Texas System | Anti-viral treatment methods using phosphatidylethanolamine-binding peptide derivatives |
| US7384909B2 (en) | 2002-07-15 | 2008-06-10 | Board Of Regents, The University Of Texas System | Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents |
| US7572448B2 (en) * | 2002-07-15 | 2009-08-11 | Board Of Regents, The University Of Texas System | Combined cancer treatment methods using selected antibodies to aminophospholipids |
| US7615223B2 (en) * | 2002-07-15 | 2009-11-10 | Board Of Regents, The University Of Texas System | Selected immunoconjugates for binding to aminophospholipids |
| US7879801B2 (en) * | 2002-07-15 | 2011-02-01 | Board Of Regents, The University Of Texas System | Compositions comprising cell-impermeant duramycin derivatives |
| US7906115B2 (en) | 2002-07-15 | 2011-03-15 | Thorpe Philip E | Combinations kits and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| US7625563B2 (en) * | 2002-07-15 | 2009-12-01 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids |
| US7622118B2 (en) | 2002-07-15 | 2009-11-24 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected antibodies to aminophospholipids |
| US7678386B2 (en) | 2002-07-15 | 2010-03-16 | Board Of Regents The University Of Texas | Liposomes coated with selected antibodies that bind to aminophospholipids |
| US7790159B2 (en) * | 2002-07-15 | 2010-09-07 | Board Of Regents, The University Of Texas System | Methods, combinations and kits for treating viral infections using immunoconjugates and antibodies to aminophospholipids |
| US7611704B2 (en) | 2002-07-15 | 2009-11-03 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| US20040131622A1 (en) * | 2002-07-15 | 2004-07-08 | Board Of Regents | Combinations and kits for treating viral infections using immunoconjugates to aminophospholipids |
| US7247303B2 (en) | 2002-07-15 | 2007-07-24 | Board Of Regents, The University Of Texas System | Selected antibody CDRs for binding to aminophospholipids |
| US7511124B2 (en) * | 2002-07-15 | 2009-03-31 | Board Of Regents, The University Of Texas System | Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents |
| US7455833B2 (en) * | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| WO2004013303A2 (en) * | 2002-08-02 | 2004-02-12 | Surromed, Inc. | Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease |
| US20040042959A1 (en) * | 2002-08-28 | 2004-03-04 | Michael Montalto | Imaging cell death in vivo using non-radionuclide contrast agents |
| US9701754B1 (en) | 2002-10-23 | 2017-07-11 | City Of Hope | Covalent disulfide-linked diabodies and uses thereof |
| US20040191215A1 (en) * | 2003-03-25 | 2004-09-30 | Michael Froix | Compositions for induction of a therapeutic response |
| EP2281577B1 (en) | 2003-05-14 | 2016-11-16 | ImmunoGen, Inc. | Drug conjugate composition |
| US20070207158A1 (en) * | 2003-06-17 | 2007-09-06 | Harrison Roger G | Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof |
| US20110002978A1 (en) | 2003-06-17 | 2011-01-06 | Harrison Roger G | Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof |
| ATE402947T1 (de) | 2003-06-25 | 2008-08-15 | Peregrine Pharmaceuticals Inc | Verfahren und vorrichtung zur kontinuierlichen radioaktiven markierung von proteinen im grossen massstab |
| US20050152906A1 (en) * | 2003-06-30 | 2005-07-14 | Avigdor Levanon | Specific human antibodies |
| US20050069955A1 (en) * | 2003-06-30 | 2005-03-31 | Daniel Plaksin | Antibodies and uses thereof |
| WO2005005954A2 (en) * | 2003-06-30 | 2005-01-20 | The Brigham & Women's Hospital, Inc. | Method, composition and kit for detecting phosphatidylserine (ps) on cell membranes |
| DE10338733A1 (de) * | 2003-08-22 | 2005-03-24 | Berdel, Wolfgang E., Prof. Dr.med. | Fusionspolypeptide und deren Verwendung für die antivaskuläre Tumortherapie |
| WO2005069935A2 (en) * | 2004-01-20 | 2005-08-04 | University Of Medicine And Dentistry Of New Jersey | METHODS FOR MEASURING TRANSFORMING GROWTH FACTOR BETA (TGF-β) RECEPTOR SIGNALING ACTIVITY AND USES THEREOF |
| WO2005079831A1 (en) * | 2004-02-13 | 2005-09-01 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of hcnp peptides for the modulation of cardio-vascular physiology and diuresis |
| US20060003020A1 (en) * | 2004-03-11 | 2006-01-05 | The Regents Of The University Of Michigan | Anti-metastatic ability of mibefradil and gadolinium |
| CA2559167A1 (en) * | 2004-03-11 | 2005-09-22 | Alavita, Inc. | Modified annexin proteins and methods for preventing thrombosis |
| US8470315B2 (en) | 2004-04-13 | 2013-06-25 | Quintessence Biosciences, Inc. | Non-natural ribonuclease conjugates as cytotoxic agents |
| US20050271726A1 (en) * | 2004-06-02 | 2005-12-08 | Albert Crum | Immune enhancing compositions and methods of use thereof |
| CA2572453A1 (en) * | 2004-06-02 | 2005-12-15 | Sidney Kimmel Cancer Center | Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface |
| US20060024315A1 (en) * | 2004-06-02 | 2006-02-02 | Sidney Kimmel Cancer Center | Vascular targets for detecting, imaging and treating neoplasia or neovasculature |
| US7511016B2 (en) * | 2004-07-07 | 2009-03-31 | Mosamedix B.V. | Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof |
| US8697139B2 (en) | 2004-09-21 | 2014-04-15 | Frank M. Phillips | Method of intervertebral disc treatment using articular chondrocyte cells |
| US20060127311A1 (en) * | 2004-11-17 | 2006-06-15 | Duke University | Radiation dosimetry and blocking antibodies and methods and uses therefor in the treatment of cancer |
| WO2006066071A2 (en) * | 2004-12-17 | 2006-06-22 | Mayo Foundation For Medical Education And Research | Prognosis of renal cell carcinoma |
| HRP20110859T1 (hr) * | 2004-12-21 | 2011-12-31 | Medimmune Limited | Protutijela usmjerena na angiopoietin-2 i njihova upotreba |
| DK1853631T3 (en) * | 2005-01-24 | 2016-03-29 | Univ Texas | Fc-FUSION CONSTRUCTIONS BINDING TO PHOSPHATIDYLSERINE AND THERAPEUTIC APPLICATION THEREOF |
| US20060182750A1 (en) | 2005-02-11 | 2006-08-17 | Immunogen, Inc. | Process for preparing stable drug conjugates |
| US7393833B2 (en) * | 2005-03-09 | 2008-07-01 | The Board Of Regents Of The University Of Oklahoma | Chimeric proteins with phosphatidylserine binding domains |
| EP1712241A1 (en) * | 2005-04-15 | 2006-10-18 | Centre National De La Recherche Scientifique (Cnrs) | Composition for treating cancer adapted for intra-tumoral administration and uses thereof |
| EP1874334A4 (en) * | 2005-04-15 | 2011-03-30 | Vascular Biogenics Ltd | COMPOSITIONS WITH BETA 2-GLYCOPROTEIN I-PEPTIDES FOR THE PREVENTION AND / OR TREATMENT OF VASCULAR DISEASES |
| US20060257317A1 (en) * | 2005-05-04 | 2006-11-16 | Duke University | Combination therapy in the treatment of cancer |
| HUE026303T2 (hu) | 2005-07-25 | 2016-06-28 | Emergent Product Dev Seattle | B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával |
| WO2007019232A2 (en) | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
| CA2893252C (en) | 2005-08-24 | 2018-05-29 | Immunogen, Inc. | Process for preparing antibody maytansinoid conjugates |
| WO2007109321A2 (en) | 2006-03-20 | 2007-09-27 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
| US20070225213A1 (en) * | 2006-03-23 | 2007-09-27 | Kosak Matthew K | Nucleic acid carriers for delivery of therapeutic agents |
| WO2007117432A2 (en) * | 2006-03-30 | 2007-10-18 | The Regents Of The University Of Michigan | Methods and compositions for modulating angiogenesis and tumor growth |
| US9789161B2 (en) * | 2006-04-28 | 2017-10-17 | Warsaw Orthopedic, Inc. | Methods for treating back or neck pain caused by NGF using a therapeutic agent consisting of ReN-1820, ALE-0540 and capsaicin |
| US8796429B2 (en) * | 2006-05-31 | 2014-08-05 | Lpath, Inc. | Bioactive lipid derivatives, and methods of making and using same |
| US9274130B2 (en) | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
| US9274129B2 (en) * | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Methods and reagents for detecting bioactive lipids |
| US9217749B2 (en) * | 2006-05-31 | 2015-12-22 | Lpath, Inc. | Immune-derived moieties reactive against lysophosphatidic acid |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| JP2009541333A (ja) * | 2006-06-23 | 2009-11-26 | クインテセンス バイオサイエンシーズ インコーポレーティッド | 修飾リボヌクレアーゼ |
| EP2049151A4 (en) | 2006-07-17 | 2010-03-24 | Quintessence Biosciences Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER |
| WO2008043018A1 (en) | 2006-10-04 | 2008-04-10 | Dana-Farber Cancer Institute, Inc. | Tumor immunity |
| US9504745B2 (en) | 2007-02-19 | 2016-11-29 | The Board Of Regents Of The University Of Oklahoma | Compositions and methods for cancer treatment using targeted carbon nanotubes |
| US8518870B2 (en) * | 2007-02-19 | 2013-08-27 | The Board Of Regents Of The University Of Oklahoma | Compositions and methods for cancer treatment using targeted carbon nanotubes |
| US20090324596A1 (en) | 2008-06-30 | 2009-12-31 | The Trustees Of Princeton University | Methods of identifying and treating poor-prognosis cancers |
| US10745701B2 (en) | 2007-06-28 | 2020-08-18 | The Trustees Of Princeton University | Methods of identifying and treating poor-prognosis cancers |
| US8334239B2 (en) | 2007-07-10 | 2012-12-18 | The Board Of Regents Of The University Of Texas System | High affinity VEGF-receptor antagonists |
| CA2698343C (en) | 2007-09-04 | 2018-06-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
| CA2698812A1 (en) * | 2007-09-14 | 2009-03-19 | Nitto Denko Corporation | Drug carriers |
| CA2702043A1 (en) * | 2007-10-08 | 2009-04-16 | Quintessence Biosciences, Inc. | Compositions and methods for ribonuclease-based therapies |
| BRPI0820298A8 (pt) | 2007-11-09 | 2018-05-08 | Affitech Res As | composições e métodos de anticorpos anti-vegf |
| CA2711691A1 (en) * | 2008-01-07 | 2009-07-16 | Patrys Limited | Barb4 target, antibody designated barb4, barb4 related antibodies, and methods of making and using same |
| AU2009234277B2 (en) | 2008-04-11 | 2014-12-04 | Aptevo Research And Development Llc | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| EP2281004A4 (en) * | 2008-04-14 | 2012-02-15 | Proscan Rx Pharma Inc | PROSTATE-SPECIFIC MEMBRANANT ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS |
| EP2334695B1 (en) | 2008-10-01 | 2015-12-23 | Quintessence Biosciences, Inc. | Therapeutic ribonucleases |
| EP2398504B1 (en) * | 2009-02-17 | 2018-11-28 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
| EP2229951A1 (en) * | 2009-03-08 | 2010-09-22 | Stichting Katholieke Universiteit | Methods for the treatment or prevention of systemic sclerosis |
| ME03479B (me) | 2009-06-03 | 2020-01-20 | Immunogen Inc | Metodi konjugacije |
| US8772459B2 (en) | 2009-12-02 | 2014-07-08 | Imaginab, Inc. | J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use |
| JP6200806B2 (ja) | 2010-05-21 | 2017-09-20 | メリマック ファーマシューティカルズ インコーポレーティッド | 二重特異的融合タンパク質 |
| ME03353B (me) | 2011-03-29 | 2019-10-20 | Immunogen Inc | Priprema konjugata antitela i majtanzinoida jednostepenim postupkom |
| AU2013326881B2 (en) | 2012-10-04 | 2018-08-02 | Immunogen, Inc. | Use of a PVDF membrane to purify cell-binding agent cytotoxic agent conjugates |
| FI3524617T3 (fi) | 2013-03-15 | 2023-06-26 | Gladiator Biosciences Inc | Gla-domeenit terapeuttisina aineina |
| US9987241B2 (en) | 2014-09-25 | 2018-06-05 | The Board Of Regents Of The University Of Oklahoma | Enzyme conjugate and prodrug cancer therapy |
| WO2016081637A1 (en) | 2014-11-18 | 2016-05-26 | Maximum Fidelity Surgica Simulations, Llc | Post mortem reconstitution of circulation |
| CN114656483A (zh) | 2014-12-04 | 2022-06-24 | 细胞基因公司 | 生物分子共轭物 |
| ES3020458T3 (en) | 2015-08-07 | 2025-05-22 | Imaginab Inc | Antigen binding constructs to target molecules |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| US10040840B2 (en) | 2015-10-02 | 2018-08-07 | Silver Creek Pharmaceuticals, Inc. | Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue |
| DK3380525T3 (da) | 2015-11-25 | 2024-01-29 | Immunogen Inc | Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf |
| US20190248920A1 (en) | 2016-09-23 | 2019-08-15 | Csl Limited | Coagulation factor binding proteins and uses thereof |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
| EP3624846B1 (en) | 2017-05-16 | 2024-08-07 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan |
| CA3070230A1 (en) | 2017-07-24 | 2019-01-31 | Rutgers, The State University Of New Jersey | Phosphatidylserine targeting fusion molecules and methods for their use |
| WO2020032951A1 (en) | 2018-08-09 | 2020-02-13 | The Board Of Regents Of The University Of Oklahoma | Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same |
| JP2020533404A (ja) | 2017-09-05 | 2020-11-19 | グラディエーター バイオサイエンシーズ インコーポレイテッド | 細胞内送達法 |
| WO2019094959A1 (en) | 2017-11-13 | 2019-05-16 | Fernandez Joss | Reconstitution of post mortem circulation, specialized methods and procedures |
| US11716989B2 (en) | 2019-04-16 | 2023-08-08 | Maximum Fidelity Surgical Simulations, LLC | Cadaver preservation systems and methods |
| US11915610B2 (en) | 2019-05-15 | 2024-02-27 | Maximum Fidelity Surgical Simulations, LLC | Cadaverous heart model |
| WO2021042022A1 (en) | 2019-08-30 | 2021-03-04 | University Of Rochester | Septin inhibitors for treatment of cancers |
| TWI843989B (zh) | 2021-02-19 | 2024-06-01 | 美商美威高能離子醫療系統公司 | 用於粒子治療系統之支架 |
| CN114807032B (zh) * | 2022-05-20 | 2023-09-12 | 南京大学 | 地塞米松诱导中性粒细胞产生的细胞外囊泡在制备治疗消炎药物中的应用 |
| WO2025027529A1 (en) | 2023-07-31 | 2025-02-06 | Advesya | Anti-il-1rap antibody drug conjugates and methods of use thereof |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4361544A (en) | 1980-03-03 | 1982-11-30 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
| US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
| US4925922A (en) | 1983-02-22 | 1990-05-15 | Xoma Corporation | Potentiation of cytotoxic conjugates |
| FR2566271B1 (fr) | 1984-06-20 | 1986-11-07 | Sanofi Sa | Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention |
| US4837003A (en) * | 1984-09-13 | 1989-06-06 | Mallinckrodt, Inc. | Radiolabeled antibody fragments |
| CA1289880C (en) | 1985-12-06 | 1991-10-01 | Jeffrey L. Winkelhake | Anti-human ovarian cancer immunotoxins and methods of use thereof |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| FR2601679B1 (fr) | 1986-07-15 | 1990-05-25 | Sanofi Sa | Immunotoxines, procede de preparation et compositions pharmaceutiques en contenant |
| EP0260148A3 (en) | 1986-09-12 | 1989-06-07 | Genentech, Inc. | Improved recombinant expression method, vector and transformed cells |
| EP0266993B1 (en) | 1986-11-04 | 1995-04-05 | Genentech, Inc. | Method and therapeutic compositions for the treatment of bleeding disorders |
| IE81149B1 (en) | 1987-02-12 | 2000-05-03 | Genentech Inc | Methods and deoxyribonucleic acid for the preparation of tissue factor protein |
| US5223427A (en) | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
| GB8800077D0 (en) | 1988-01-05 | 1988-02-10 | Ciba Geigy Ag | Novel chimeric antibodies |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US4867962A (en) | 1988-02-26 | 1989-09-19 | Neorx Corporation | Functionally specific antibodies |
| US5024834A (en) | 1988-07-12 | 1991-06-18 | Cetus Corporation | Thioether linked immunotoxin conjugates |
| US5135736A (en) | 1988-08-15 | 1992-08-04 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
| IL91933A (en) | 1988-10-11 | 1994-12-29 | Univ Southern California | Their immuno-bracelet and isophiles which are beneficial in increasing vascular permeability or blood supply to tumor or otherwise damaged tissue |
| US5632991A (en) | 1988-11-14 | 1997-05-27 | Brigham & Women's Hospital | Antibodies specific for E-selectin and the uses thereof |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5134075A (en) | 1989-02-17 | 1992-07-28 | Oncogen Limited Partnership | Monoclonal antibody to novel antigen associated with human tumors |
| US5272263A (en) | 1989-04-28 | 1993-12-21 | Biogen, Inc. | DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
| US6020145A (en) | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
| ATE89169T1 (de) | 1989-07-15 | 1993-05-15 | Boehringer Ingelheim Int | Antikoagulanz enthaltendes mittel. |
| US5166319A (en) | 1989-10-10 | 1992-11-24 | Brunswick Corporation | Interfacial condensation of bioactive compounds and the site-specific compounds and conjugates thereof |
| DE3937607A1 (de) | 1989-11-11 | 1991-05-16 | Boehringer Ingelheim Int | Verwendung eines antikoagulanz zur behandlung von tumorerkrankungen |
| US5165923A (en) | 1989-11-20 | 1992-11-24 | Imperial Cancer Research Technology | Methods and compositions for the treatment of hodgkin's disease |
| US5627036A (en) | 1989-12-27 | 1997-05-06 | Boehringer Ingelheim International Gmbh | Use of an anticoagulant as a diagnostic agent |
| WO1991015772A1 (en) | 1990-04-06 | 1991-10-17 | Yamasa Shoyu Co. Ltd. | Methods for determining phospholipids and antibodies thereof |
| DE69122777T2 (de) | 1990-07-20 | 1997-04-10 | Pharmacia & Upjohn Ab, Stockholm | Zielgerichtete spezifische antikörper-superantigen konjugate und ihre präparation |
| HU215389B (hu) * | 1990-09-06 | 1998-12-28 | Schering Corp. | Eljárás hatóanyagként IL-4-et tartalmazó tömött tumorok kezelésére alkalmas gyógyszerkészítmények előállítására |
| AU1269092A (en) | 1991-01-24 | 1992-08-27 | Cytel Corporation | Monoclonal antibodies to elam-1 and their uses |
| US5374617A (en) | 1992-05-13 | 1994-12-20 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with FVIIa |
| US5504064A (en) | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
| US5399338A (en) * | 1991-05-01 | 1995-03-21 | University Of New Mexico | Enhancement of abnormal tissue uptake of antibodies, tumor-specific agents or conjugates thereof for diagnostic imaging or therapy |
| US5632986A (en) | 1991-05-09 | 1997-05-27 | The University Of Washington | Phospholipid-targeted thrombolytic agents |
| US5346991A (en) | 1991-06-13 | 1994-09-13 | Genentech, Inc. | Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US6004555A (en) | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for the specific coagulation of vasculature |
| US6036955A (en) | 1992-03-05 | 2000-03-14 | The Scripps Research Institute | Kits and methods for the specific coagulation of vasculature |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| CA2131528C (en) | 1992-03-05 | 2004-07-13 | Philip E. Thorpe | Methods and compositions for targeting the vasculature of solid tumors |
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US6093399A (en) | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
| US5877289A (en) | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
| US6329507B1 (en) | 1992-08-21 | 2001-12-11 | The Dow Chemical Company | Dimer and multimer forms of single chain polypeptides |
| EP0669988B2 (en) | 1992-10-29 | 2009-07-08 | The Australian National University | Angiogenesis inhibitory antibodies |
| US5512269A (en) | 1993-06-09 | 1996-04-30 | Burroughs Wellcome, Co. | Method of treating retained pulmonary secretions |
| US5968477A (en) | 1994-01-24 | 1999-10-19 | Neorx Corporation | Radiolabeled annexin conjugates with hexose and a chelator |
| ATE237366T1 (de) | 1994-01-24 | 2003-05-15 | Neorx Corp | Radioaktiv-markierte annexine |
| AU1919295A (en) | 1994-02-14 | 1995-08-29 | Indiana University Foundation | Aminophospholipid compositions and uses thereof |
| NZ283171A (en) | 1994-04-11 | 1998-02-26 | Nexins Research Bv | Detecting or quantifying apoptotic cells in a sample |
| US5830448A (en) | 1994-06-16 | 1998-11-03 | Genentech, Inc. | Compositions and methods for the treatment of tumors |
| EP0765166B1 (en) | 1994-06-16 | 2003-05-21 | Neorx Corporation | Radiolabeled annexin-galactose conjugates |
| ES2153483T3 (es) * | 1994-07-11 | 2001-03-01 | Univ Texas | Metodos y composiciones para la coagulacion especifica en los vasos tumorales. |
| WO1996017618A1 (en) | 1994-12-07 | 1996-06-13 | Neorx Corporation | Radiolabeled annexin-galactose cluster conjugates |
| US5658877A (en) | 1995-05-18 | 1997-08-19 | Wisconsin Alumni Research Foundation | Method to treat endotoxin effects by administration of 33 kilodalton phospholipid binding protein |
| DE19541284C2 (de) | 1995-11-06 | 1998-09-24 | Kalden Joachim Robert Prof Dr | Verfahren zur Immunmodulation |
| IL117223A0 (en) | 1996-02-22 | 1996-06-18 | Yeda Res & Dev | Antipathogenic polypeptides and compositions comprising them |
| EP0932390A1 (en) | 1996-10-11 | 1999-08-04 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
| WO1998029453A1 (en) * | 1996-12-27 | 1998-07-09 | Mochida Pharmaceutical Co., Ltd. | Cell membrane-directed drugs |
| US5922688A (en) | 1997-01-10 | 1999-07-13 | Board Of Regents, The University Of Texas System | PEA3 is a tumor suppressor |
| CN1252808A (zh) | 1997-02-20 | 2000-05-10 | 耶达研究及发展有限公司 | 抗病原合成肽及包含该肽类的组合物 |
| WO1999035158A1 (en) | 1998-01-07 | 1999-07-15 | Human Genome Sciences, Inc. | 36 human secreted proteins |
| US6005083A (en) * | 1997-03-28 | 1999-12-21 | Neorx Corporation | Bridged aromatic substituted amine ligands with donor atoms |
| HUP0001261A3 (en) | 1997-04-30 | 2001-11-28 | Univ Washington Seattle | Method of imaging cell death in vivo |
| US6057435A (en) | 1997-09-19 | 2000-05-02 | Genentech, Inc. | Tie ligand homologues |
| US20030060612A1 (en) | 1997-10-28 | 2003-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US6300308B1 (en) | 1997-12-31 | 2001-10-09 | Board Of Regents, The University Of Texas System | Methods and compositions for inducing autoimmunity in the treatment of cancers |
| CA2331789C (en) * | 1998-07-13 | 2013-09-10 | Board Of Regents, The University Of Texas System | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| US6818213B1 (en) | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
| US6406693B1 (en) | 1998-07-13 | 2002-06-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
| EP1131106B1 (en) | 1998-11-12 | 2009-06-24 | Novolytics Inc. | Compositions and methods for producing vascular occlusion |
| WO2000033888A2 (en) | 1998-12-11 | 2000-06-15 | Coulter Pharmaceutical, Inc. | Prodrug compounds and process for preparation thereof |
| US6333348B1 (en) | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
| US6824780B1 (en) | 1999-10-29 | 2004-11-30 | Genentech, Inc. | Anti-tumor antibody compositions and methods of use |
| US7740841B1 (en) | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
| US20020025319A1 (en) | 2000-03-14 | 2002-02-28 | Peter Brams | Antibodies that bind phosphatidyl serine and a method of their use |
| US20030129223A1 (en) | 2000-10-11 | 2003-07-10 | Targesome, Inc. | Targeted multivalent macromolecules |
| US20030133972A1 (en) | 2000-10-11 | 2003-07-17 | Targesome, Inc. | Targeted multivalent macromolecules |
| IL139720A0 (en) | 2000-11-16 | 2002-02-10 | Yeda Res & Dev | Diastereomeric peptides and pharmaceutical compositions comprising them |
| CA2463816C (en) | 2001-10-19 | 2014-07-08 | Vascular Biogenics Ltd. | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| US7399743B2 (en) | 2001-10-26 | 2008-07-15 | The Scripps Research Institute | Targeted thrombosis |
| EP1476752A4 (en) | 2002-02-27 | 2008-02-13 | Bio Merieux Inc | METHOD FOR DIAGNOSING AND MONITORING HEMOSTATIC DYSFUNCTION, SEVERE INFECTION AND SYSTEMATIC INFLAMMATORY RESPONSE SYNDROME |
| WO2005019429A2 (en) | 2003-08-22 | 2005-03-03 | Potentia Pharmaceuticals, Inc. | Compositions and methods for enhancing phagocytosis or phagocyte activity |
-
1999
- 1999-07-12 CA CA2331789A patent/CA2331789C/en not_active Expired - Fee Related
- 1999-07-12 IL IL14070099A patent/IL140700A0/xx not_active IP Right Cessation
- 1999-07-12 US US09/351,457 patent/US6312694B1/en not_active Expired - Lifetime
- 1999-07-12 AT AT99935491T patent/ATE230614T1/de active
- 1999-07-12 EP EP99935491A patent/EP1098665B9/en not_active Expired - Lifetime
- 1999-07-12 WO PCT/US1999/015668 patent/WO2000002587A1/en not_active Ceased
- 1999-07-12 AU AU50958/99A patent/AU750414B2/en not_active Ceased
- 1999-07-12 DE DE69904831T patent/DE69904831T2/de not_active Expired - Lifetime
- 1999-07-12 US US09/351,149 patent/US7067109B1/en not_active Expired - Lifetime
- 1999-07-12 JP JP2000558846A patent/JP2002520297A/ja active Pending
- 1999-07-12 BR BR9912053-4A patent/BR9912053A/pt not_active Application Discontinuation
- 1999-07-12 NZ NZ508873A patent/NZ508873A/en not_active IP Right Cessation
- 1999-07-12 ES ES99935491T patent/ES2188202T3/es not_active Expired - Lifetime
-
2001
- 2001-03-28 US US09/819,386 patent/US6783760B1/en not_active Expired - Lifetime
-
2005
- 2005-10-19 US US11/254,137 patent/US8709430B2/en not_active Expired - Fee Related
-
2010
- 2010-01-29 JP JP2010019796A patent/JP5478285B2/ja not_active Expired - Fee Related
-
2012
- 2012-11-30 JP JP2012262623A patent/JP5721693B2/ja not_active Expired - Fee Related
-
2014
- 2014-03-05 US US14/197,672 patent/US20140205544A1/en not_active Abandoned
-
2016
- 2016-03-24 US US15/079,700 patent/US20160199509A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010143941A5 (enExample) | ||
| Brenner et al. | Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude | |
| Kumari et al. | Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics | |
| Lammers et al. | Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy | |
| Connell et al. | Selective permeabilization of the blood–brain barrier at sites of metastasis | |
| Shinkai et al. | Targeting hyperthermia for renal cell carcinoma using human MN antigenspecific magnetoliposomes | |
| Huang et al. | A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice | |
| CA2591914C (en) | Fc-fusion constructs binding to phosphatidylserine and their therapeutic use | |
| US6159443A (en) | X-ray guided drug delivery | |
| Deng et al. | Advances in the treatment of atherosclerosis with ligand‐modified nanocarriers | |
| Loi et al. | Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma | |
| JP2002520297A5 (enExample) | ||
| ES2529660T3 (es) | Métodos de tratamiento en los que se utilizan las proteínas de unión a albúmina como dianas | |
| Chen et al. | A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma | |
| JP4576005B2 (ja) | 腫瘍および炎症性疾患を選択的に治療するために用いられる、壊死を引き起こす物質と、壊死により活性化される物質との組み合わせ | |
| MXPA05000652A (es) | Anticuerpos seleccionados y peptidos de duramicina que se enlazan a fosfolipidos anionicos y aminofosfolipidos y sus usos en el tratamiento de infecciones virales y del cancer. | |
| Khoshnejad et al. | Vascular accessibility of endothelial targeted ferritin nanoparticles | |
| Pinho et al. | Stem cells as vehicles and targets of nanoparticles | |
| US20250043023A1 (en) | Targeting moiety-drug grafted immune cell compositions and methods of use | |
| Ruoslahti | Access granted: iRGD helps silicasome-encased drugs breach the tumor barrier | |
| Toomajian et al. | Magnetic particle imaging reveals that iron-labeled extracellular vesicles accumulate in brains of mice with metastases | |
| Muradova et al. | Targeted-theranostic nanoparticles induce anti-tumor immune response in lung cancer | |
| EP4525834A1 (en) | Endothelial damage and nanoparticle targeting: compositions, processes, uses | |
| Chen et al. | Bone-seeking albumin-nanomedicine for in vivo imaging and therapeutic monitoring | |
| Pathak et al. | Antibody-mediated drug delivery systems: concepts, technology, and applications |